Litcius/Paper detail

704MO Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone with 1L chemotherapy (CTx) for advanced urothelial carcinoma (UC): Subgroup analyses from JAVELIN Bladder 100

Petros Grivas, S.H. Park, Éric Voog, Claudia Caserta, Begoña P. Valderrama, Howard Gurney, Haralabos P. Kalofonos, Siniša Radulović, Wim Demey, Anders Ullén, Yohann Loriot, Srikala S. Sridhar, Norihiko Tsuchiya, Evgeny Kopyltsov, Shilpa Gupta, Bo Huang, Nuno Costa, John A. Blake-Haskins, Alessandra di Pietro, Thomas Powles

2020Annals of Oncology14 citationsDOI

Topics & Concepts

MedicineInternal medicineAvelumabRandomizationHazard ratioGastroenterologyMetastatic Urothelial CarcinomaClinical endpointCarboplatinUrologyBladder cancerChemotherapyRandomized controlled trialOncologyUrothelial carcinomaCisplatinCancerNivolumabImmunotherapyConfidence intervalBladder and Urothelial Cancer TreatmentsUrinary and Genital Oncology StudiesCancer Immunotherapy and Biomarkers
704MO Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone with 1L chemotherapy (CTx) for advanced urothelial carcinoma (UC): Subgroup analyses from JAVELIN Bladder 100 | Litcius